JP2015535243A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535243A5
JP2015535243A5 JP2015539556A JP2015539556A JP2015535243A5 JP 2015535243 A5 JP2015535243 A5 JP 2015535243A5 JP 2015539556 A JP2015539556 A JP 2015539556A JP 2015539556 A JP2015539556 A JP 2015539556A JP 2015535243 A5 JP2015535243 A5 JP 2015535243A5
Authority
JP
Japan
Prior art keywords
melphalan flufenamide
flufenamide hydrochloride
lyophilized pharmaceutical
sucrose
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015539556A
Other languages
English (en)
Japanese (ja)
Other versions
JP6284945B2 (ja
JP2015535243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2013/051246 external-priority patent/WO2014065751A1/en
Publication of JP2015535243A publication Critical patent/JP2015535243A/ja
Publication of JP2015535243A5 publication Critical patent/JP2015535243A5/ja
Application granted granted Critical
Publication of JP6284945B2 publication Critical patent/JP6284945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015539556A 2012-10-26 2013-10-24 メルファランフルフェナミドの凍結乾燥製剤 Active JP6284945B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261719184P 2012-10-26 2012-10-26
SE1251211 2012-10-26
US61/719,184 2012-10-26
SE1251211-7 2012-10-26
PCT/SE2013/051246 WO2014065751A1 (en) 2012-10-26 2013-10-24 Lyophilized preparations of melphalan flufenamide

Publications (3)

Publication Number Publication Date
JP2015535243A JP2015535243A (ja) 2015-12-10
JP2015535243A5 true JP2015535243A5 (enExample) 2016-11-10
JP6284945B2 JP6284945B2 (ja) 2018-02-28

Family

ID=50544986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539556A Active JP6284945B2 (ja) 2012-10-26 2013-10-24 メルファランフルフェナミドの凍結乾燥製剤

Country Status (18)

Country Link
US (2) US10285946B2 (enExample)
EP (2) EP3628318A1 (enExample)
JP (1) JP6284945B2 (enExample)
KR (1) KR102205592B1 (enExample)
CN (2) CN104994847B (enExample)
AU (1) AU2013335359B2 (enExample)
BR (1) BR112015009280B1 (enExample)
CA (1) CA2889753C (enExample)
CY (1) CY1122483T1 (enExample)
IL (1) IL238398B (enExample)
MX (1) MX365205B (enExample)
NZ (1) NZ708016A (enExample)
PL (1) PL2928463T3 (enExample)
RS (1) RS60068B1 (enExample)
RU (1) RU2643762C2 (enExample)
SI (1) SI2928463T1 (enExample)
SM (1) SMT202000058T1 (enExample)
WO (1) WO2014065751A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037863T2 (hu) 2011-04-28 2018-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
AU2019243707B2 (en) 2018-03-29 2023-12-07 Airway Therapeutics, Inc. Methods and compositions comprising surfactant protein D (SP-D)
US12385894B2 (en) 2018-03-29 2025-08-12 Airway Therapeutics, Inc. Systems and methods for characterizing surfactant protein D (SP-D) oligomers
MA53904A (fr) * 2018-10-18 2021-08-25 Oncopeptides Ab Composés contenant du deutérium
JP2022527532A (ja) 2019-04-03 2022-06-02 オンコペプティデス エービー メルフルフェンによるalアミロイドーシスの治療
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
EP4366721A1 (en) 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
KR102757193B1 (ko) * 2021-10-19 2025-01-21 단국대학교 천안캠퍼스 산학협력단 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
DE60141398D1 (de) * 2000-06-13 2010-04-08 Oncopeptides Ab Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
EP1438019A1 (en) * 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AR061969A1 (es) * 2006-07-07 2008-08-10 Gilead Sciences Inc Derivados halogenados de imidazo-piridino, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes anti vhc
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
CA2832410C (en) 2011-04-15 2019-07-23 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
HUE037863T2 (hu) 2011-04-28 2018-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes

Similar Documents

Publication Publication Date Title
JP2015535243A5 (enExample)
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
JP2016510326A5 (enExample)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2014077003A5 (enExample)
WO2017100700A3 (en) Peptides for renal therapy
UA114907C2 (uk) Гетероциклільні сполуки як інгібітори mek
HRP20221355T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
EP4371615A3 (en) Treatment of amd using aav sflt-1
JP2017531619A5 (enExample)
WO2009043476A3 (en) Neuromedin s as a therapeutic agent
JP2017537066A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2015078220A5 (enExample)
JP2014525449A5 (enExample)
HK1254645A1 (zh) 冻乾药物组合物
JP2017532343A5 (enExample)
RU2017123880A (ru) Антагонисты миостатина или активина для лечения саркопении
RU2017132330A (ru) Соли производного хиназолина и способ их получения
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
PH12020550041A1 (en) Drug compound and purification methods thereof
RU2016127558A (ru) Стероидное соединение для применения в лечении печеночной энцефалопатии
WO2016184577A3 (en) Dry powder composition comprising long-chain rna